Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to compare GnRH-agonist trigger with dual GnRH-agonist and HCG trigger in oocyte donors. The main questions it aims to answer are: - Maturation rate (Metaphase II/ Total number of COCs collected) - Fertilization rate - Embryo quality day 3 - Fragmentation rate embryo day 3 - Blastulation rate (Day5/6/7) - Quality of blastocyst (Gardner criteria) Participants will undergo controlled ovarian stimulation with a GnRH antagonist protocol Researchers will compare the effects of final maturation with GnRH-agonist trigger to a dual trigger (hCG and GnRH-a)


Clinical Trial Description

Final oocyte maturation is a critical step in the process of the Assisted Reproductive Technology (ART) treatment and has a certain impact on oocyte yield and oocyte competency. There are three different types of trigger: hCG, GnRH-agonist or dual trigger (hCG and GnRH-agonist combined), and the choice depends on the ovarian stimulation protocol, the ovarian response and on the clinical standard of the IVF clinic. As oocyte donors are at high risk for OHSS, a GnRH-agonist trigger (GnRH-a) is the most commonly used modality for triggering final maturation. However, a certain number of oocyte donors may have a suboptimal response to GnRH-a trigger only, with a yield of oocytes less than the 10th percentile, with a clear negative impact on oocyte efficiency and competency. This study aims to evaluate whether oocyte competence can be improved in oocyte donors with a previously suboptimal response to GnRH-a, by using a dual trigger in a subsequent ovarian stimulation cycle, in which hCG is added to the GnRH-agonist for final maturation ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06142708
Study type Interventional
Source Embryolab Fertility Clinic
Contact
Status Recruiting
Phase N/A
Start date November 1, 2023
Completion date February 2026

See also
  Status Clinical Trial Phase
Completed NCT01121991 - A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies Phase 3
Not yet recruiting NCT04539067 - Effect of Controlled Ovarian Stimulation in Quality of Oocyte and Embryo Phase 2
Recruiting NCT02715336 - Efficacy and Safety of Medication Used to Stimulate Ovulation Phase 4
Not yet recruiting NCT03298750 - Mechanical Stimulation of the Ovary for Infertility Treatment in Patients With Very Low Ovarian Reserve N/A
Completed NCT03939403 - Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor Phase 4
Recruiting NCT05166668 - Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle N/A
Completed NCT04549649 - The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response N/A
Terminated NCT01816789 - Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles Phase 4
Completed NCT00823004 - Antagonist/Letrozole in Poor Responders Phase 1/Phase 2
Not yet recruiting NCT06175832 - PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study Phase 4
Completed NCT00830492 - Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist Phase 4
Completed NCT01145144 - Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment N/A
Completed NCT01037699 - Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles Phase 3
Completed NCT00829075 - Impact of Three Different Gonadotrophin Regimes on Egg Donation Program Phase 4
Completed NCT01112358 - Lutropin Alfa in Women at Risk of Poor Response Phase 2
Recruiting NCT03400722 - Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response Phase 4
Completed NCT00669786 - Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles Phase 3